CD8A and neoplasm: In contrast, CD8+ T cells, dendritic cells (DCs), regulatory T cells (Tregs), and tumor-associated macrophages (TAMs) experienced a reduction in frequency upon combination TH-302 and αVEGFR-2 therapy compared with their untreated counterparts (Supplemental Figure 4D).